LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 02:50:29 2024-05-15 pm EDT			5-day change	1st Jan Change
0.02 ^USD	+10.50%		-9.09%	-68.20%

Jan. 08	Top Midday Decliners	MT
Jan. 08	LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index	CI

LumiraDx Limited Reports Earnings Results for the First Quarter Ended March 31, 2023

May 16, 2023 at 07:52 am EDT

LumiraDx Limited reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 22.17 million compared to USD 126.41 million a year ago. Net loss was USD 44.21 million compared to USD 55.75 million a year ago.

Basic loss per share from continuing operations was USD 0.14 compared to USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.22 a year ago.

Latest news about LumiraDx Limited

Top Midday Decliners	Jan. 08	MT
LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index	Jan. 08	CI
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	Jan. 02	MT
Top Premarket Decliners	Jan. 02	MT
Roche to buy part of LumiraDx diagnostics platform for $295 million	Dec. 29	RE
LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche	Dec. 29	DJ
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01	MT
Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday	Dec. 01	MT
Top Premarket Decliners	Dec. 01	MT
LumiraDx Limited Announces Resignation of Lu Huang from the Board of Directors	Nov. 07	CI
LumiraDx Limited Announces Board Appointments	Nov. 06	CI
LumiraDx Limited Appoints Veronique Ameye as the Company?s Chief Executive Officer and General Counsel, Effective as of November 1, 2023	Nov. 06	CI
LumiraDx Limited Announces Board Resignations	Nov. 01	CI
LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer	Nov. 01	CI
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth	23-10-23	MT
LumiraDx to Partner With AstraZeneca, Everton Charity Arm For Heart And Lung Screening Hub	23-10-23	MT
Investors Await Economic, Inflation Data as US Futures Trend Lower in Monday's Premarket	23-10-23	MT
Top Premarket Gainers	23-10-23	MT
LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors	23-09-26	CI
LumiraDx Limited(NasdaqGM:LMDX) dropped from S&P Global BMI Index	23-09-18	CI
Raymond James Adjusts LumiraDx Price Target to $0.80 From $1, Maintains Outperform Rating	23-08-28	MT
Transcript : LumiraDx Limited, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Earnings Flash (LMDX) LUMIRADX Reports Q2 Revenue $21M, vs. Street Est of $21.5M	23-08-24	MT
LumiraDx Limited Announces Executive Changes	23-08-24	CI
LumiraDx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI

Chart LumiraDx Limited

Duration

Period

More charts

Company Profile

LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The Company offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. It also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
LUMIRADX LIMITED	-68.20%	6.49M
THERMO FISHER SCIENTIFIC	+13.01%	227B
DANAHER CORPORATION	+13.77%	192B
INTUITIVE SURGICAL, INC.	+18.13%	136B
BOSTON SCIENTIFIC CORPORATION	+28.33%	108B
SIEMENS HEALTHINEERS AG	+1.67%	64.07B
EDWARDS LIFESCIENCES CORPORATION	+17.82%	52.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B
AGILENT TECHNOLOGIES, INC.	+10.79%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+6.08%	36.75B

Other Advanced Medical Equipment & Technology